MREO Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 123323 min ago

@ $3.74

Išleistas: 14 vas. 2024 @ 19:33

Grąža: -12.57%

Ankstesnis signalas: vas. 14 - 18:06

Ankstesnis signalas: Pardavimas

Grąža: 0.00 %

Live Chart Being Loaded With Signals

Commentary (9 geg. 2024 @ 23:00):

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally...

Stats
Šios dienos apimtis	499 463
Vidutinė apimtis	1.17M
Rinkos kapitalizacija	457.99M
EPS	$0 ( 2024-03-26 )
Kita pelno data	( $0 ) 2024-05-21
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-16.35
ATR14	$0.00500 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-08	Ekblom Anders	Buy	45 000	Share Options (Right to buy)
2024-02-08	Ekblom Anders	Buy	19 471	Deferred Restricted Stock Units
2024-02-08	Jacquet Pierre	Buy	45 000	Share Options (Right to buy)
2024-02-08	Jacquet Pierre	Buy	15 553	Deferred Restricted Stock Units
2024-02-08	Yoskowitz Marc J	Buy	45 000	Share Options (Right to buy)

INSIDER POWER
-60.62
Last 97 transactions
Buy: 2 158 393 \| Sell: 9 188 547

Tūris Koreliacija

Ilgas: 0.12 (neutral)

Trumpas: -0.21 (neutral)

Signal:(54.729) Neutral

Mereo BioPharma Group plc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
CFBK	0.888
SLNO	0.887
PBPB	0.885
PROV	0.873
ECOR	0.867
ARDX	0.865
RBKB	0.861
ISTR	0.854
CXDO	0.854
CPLP	0.851

10 Labiausiai neigiamai susiję koreliacijos
OSMT	-0.878
PFBI	-0.858
HCM	-0.847
MLVF	-0.847
IQ	-0.844
RMRM	-0.843
BFRI	-0.838
COCO	-0.833

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Mereo BioPharma Group plc Koreliacija - Valiuta/Žaliavos

-0.37
( neutral )

-0.29
( neutral )

0.00
( neutral )

0.49
( neutral )

0.50
( neutral )

Mereo BioPharma Group plc Finansinės ataskaitos

Annual	2023
Pajamos:	$10.00M
Bruto pelnas:	$7.43M (74.26 %)
EPS:	$0

FY	2023
Pajamos:	$10.00M
Bruto pelnas:	$7.43M (74.26 %)
EPS:	$0

FY	2022
Pajamos:	$1.51M
Bruto pelnas:	$571 000 (37.89 %)
EPS:	$-0.280

FY	2021
Pajamos:	$36.46M
Bruto pelnas:	$18.56M (50.89 %)
EPS:	$0.159

Financial Reports:

No articles found.

Mereo BioPharma Group plc

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.